A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia

Nutrition

Volumn 18, Issue 2, 2002, Pages 201-204

  Keithley, Joyce K ^a   Swanson, Barbara ^a   Sha, Beverly E ^b   Zeller, Janice M ^a,c   Kessler, Harold A ^b   Smith, Kimberly Y ^b  

^a RUSH UNIVERSITY COLLEGE OF NURSING   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

Cholestin; Dietary supplement; Dyslipidemia; Efficacy; Safety

Indexed keywords

CD4 ANTIGEN; CHOLESTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFECTION PREVENTION; LIVER FUNCTION TEST; LONG TERM CARE; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL PRODUCTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIVER FUNCTION TESTS; MALE; PILOT PROJECTS; SAFETY; TREATMENT OUTCOME; TRIGLYCERIDES; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036174893     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(01)00688-8     Document Type: Article

References (32)

1. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
2. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
3. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
5. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
6. Marked hyperlipidemia on ritonavir therapy
7. Lipid evaluation and glucose metabolism in HIV-1 positive patients treated with protease inhibitors
8. Severe premature coronary artery disease with protease inhibitors
9. Incidence of and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor
10. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study
11. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
12. Hyperlipidemia under treatment with proteinase inhibitors
13. Cardiovascular epidemiology in the context of HIV disease
14. Do protease inhibitors increase the risk for coronary heart disease among HIV-positive patients?
15. Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors
16. Endothelial dysfunction is associated with the use of human immunodeficiency virus-1 protease inhibitors
17. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidemias: A pilot study
18. Gemfibrozil effectively lowers protease-inhibitor-associated hypertriglyceridemia in HIV-1 positive patients
19. Interventions for hyperlipidemia associated with protease inhibitors
20. A randomised open label comparative trial of dietary advice with and without pravastatin for the management of protease inhibitor (PI)-associated hypercholesterolaemia
21. Atorvastatin for protease inhibitor-related hyperlipidemia
22. Validity and reliability of self-reported physical activity status: The Lipid Research Clinics questionnaire
23. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
24. Elderly patients with primary hyperlipidemia benefited from treatment with a Monascus purpureus rice preparation: A placebo-controlled, double-blind clinical trial
25. A multi-center, self-controlled study of Cholestin in subjects with elevated cholesterol
26. Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up